Open AccessSignificant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab
Author(s) -
Jérôme Rollin,
Audrey Payancé,
Valérie GouilleuxGruart,
Michelle Boisdron-Celle,
Nicolas Azzopardi,
Alain Morel,
Yves Gruel,
Gilles Paintaud,
Érick Gamelin,
Hervé Watier,
Thierry Lecomte
Publication year - 2015
Publication title -
pharmacogenomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.541
H-Index - 91
eISSN - 1744-8042
pISSN - 1462-2416
DOI - 10.2217/pgs.15.139
Subject(s) - cetuximab , folfiri , colorectal cancer , oncology , medicine , regimen , bevacizumab , chemotherapy , cancer , oxaliplatin
The efficacy of a cetuximab-based regimen used to treat metastatic colorectal cancer (mCRC) could be influenced by VEGFA polymorphisms.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom